Presentation is loading. Please wait.

Presentation is loading. Please wait.

Partitioned survival plots for the (A) trifluridine/tipiracil group and (B) placebo group in RECOURSE. REL, relapse state (from progression until death); TOX,

Published byRobin Émond Modified over 5 years ago

Similar presentations

Presentation on theme: "Partitioned survival plots for the (A) trifluridine/tipiracil group and (B) placebo group in RECOURSE. REL, relapse state (from progression until death); TOX,"— Presentation transcript:

1 Partitioned survival plots for the (A) trifluridine/tipiracil group and (B) placebo group in RECOURSE. REL, relapse state (from progression until death); TOX, toxicity related to grade 3/4 adverse nausea, vomiting, diarrhea, fatigue/asthaenia, anorexia, or febrile neutropaenia before progression; TWIST, time without symptoms or toxicity. Partitioned survival plots for the (A) trifluridine/tipiracil group and (B) placebo group in RECOURSE. REL, relapse state (from progression until death); TOX, toxicity related to grade 3/4 adverse nausea, vomiting, diarrhea, fatigue/asthaenia, anorexia, or febrile neutropaenia before progression; TWIST, time without symptoms or toxicity. Josep Tabernero et al. ESMO Open 2017;2:e000284 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Partitioned survival plots for the (A) trifluridine/tipiracil group and (B) placebo group in RECOURSE. REL, relapse state (from progression until death); TOX,"

Similar presentations

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
(A) Safety profile overview.

(A) Safety profile overview.
Overview of the QTWiST method

Overview of the QTWiST method
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram
Kaplan-Meier curves for overall survival (OS) probability.

Kaplan-Meier curves for overall survival (OS) probability.
Methods distribution among the three EQAs

Methods distribution among the three EQAs
Plot with best overall response and study duration.

Plot with best overall response and study duration.

Similar presentations

Ads by Google